MDXG
MIMEDX GROUP, INC.
NASDAQ · Healthcare · Biotechnology · US
$3.97
+0.51%Next report
Analyst consensus
- Next report date
- Feb 24, 2027
- EPS estimate
- $0.02
- Revenue estimate
- $70.9M
Latest reported
- Last report date
- Oct 28, 2026
- EPS actual
- -$0.01
- EPS estimate
- $0.00
- Revenue actual
- $62.3M
- Revenue estimate
- $70.7M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 3
- Avg surprise (4Q)
- -907.8%
- Revenue beats (12Q)
- 7
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $8.00
- PT range
- $8.00 – $8.00
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Oct 28, 2026 | $0.00 | -$0.01 | Miss -3671.43% | $62.3M |
| Jul 29, 2026 | -$0.05 | -$0.05 | Miss -1.01% | $64.4M |
| Apr 29, 2026 | -$0.07 | -$0.05 | Beat 28.57% | $59.0M |
| Feb 25, 2026 | $0.09 | $0.10 | Beat 12.67% | $118.1M |
| Oct 29, 2025 | $0.07 | $0.15 | Beat 114.29% | $113.7M |
| Jul 30, 2025 | $0.06 | $0.10 | Beat 66.67% | $98.6M |
| Apr 30, 2025 | $0.06 | $0.06 | In line | $88.2M |
| Feb 26, 2025 | $0.07 | $0.07 | In line | $92.9M |
| Oct 30, 2024 | $0.04 | $0.05 | Beat 13.64% | $84.1M |
| Jul 31, 2024 | $0.08 | $0.08 | In line | $87.2M |
| Apr 30, 2024 | $0.05 | $0.07 | Beat 40.00% | $84.7M |
| Feb 28, 2024 | $0.08 | $0.04 | Miss -50.00% | $86.8M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 24, 2027